Abstract:OBJECTIVE:To explore the circadian blood pressure (BP) profile and its influencing factors in essential hypertensive patients after treatment. METHODS:Cross-sectional surveillance was carried out in essential hypertensive subjects after treatment whose clinic blood pressure had been under control as 140/90 mm Hg (1 mm Hg = 0.133 kPa) for at least one month. All patients underwent a twenty-four-hour ambulatory blood pressure monitoring device (spacelabs 90207). The nocturnal fall of blood pressure (BP) was calculated from (daytime mean BP-night-time mean BP)/daytime BP, while 'daytime' values were recorded between 6 h and 22 h and 'night-time' values between 22 h and 6 h. Non-dippers were defined as those whose nocturnal decrease in mean systolic BP and/or mean diastolic BP was < 10% of the daytime BP. Binary logistic regression analysis was used to evaluate the correlation between circadian blood pressure profile and factors as gender, age, height, body mass index (BMI), family history of premature cardiovascular disease, women under age 65 or men under age 55, smoking habits, grade of hypertension, and strategy of antihypertensive drugs. RESULTS:208 treated essential hypertensive patients were enrolled in the study. 79 individuals were dippers and 129 were non-dippers. Data from logistic regression analysis showed that four factors as age, premature family history of cardiovascular disease, overweight or obesity, and strategy of antihypertensive drugs were significantly influencing the circadian blood pressure profile in treated hypertensive patients. The incidence of non-dippers in patients of 70 years of age or older and those between 60 and 69 were 3.3 and 2.3 times of those with less than 60 (P = 0.009 and 0.031, respectively). The prevalence of non-dippers in patients with a premature family history of cardiovascular disease was 3.7 times greater than those in subjects without a premature history of cardiovascular disease (P = 0.029). Similarly, the incidence of non-dippers in patients of overweight (24 = BMI < 28) and obesity (BMI >/= 28) were 3.0 and 4.8 times of those in subjects of normal weight (P = 0.003 and 0.009, respectively). Compared with patients treated with long-acting calcium channel blockers (CCBs), patients treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) alone had less prevalence of nondippers (OR = 0.139, P = 0.010). Patients treated with joint antihypertensive scheme including ACE inhibitors or ARBs(but not including diuretics) had the tendency of lower incidence of abnormal circadian blood pressure rhythm (OR = 0.453, P = 0.118). Patients treated with joint antihypertensive scheme including diuretics (not including ACE inhibitors or ARBs) and with joint antihypertensive strategy including diuretics and ACE inhibitors or ARBs had lower incidence of nondippers (OR = 0.378 and 0.273, respectively; P = 0.030 and 0.011, respectively). CONCLUSIONS:Approximately 2/3 treated essential hypertensive patients had a non-dipper blood pressure profile. Age, premature family history of cardiovascular disease, overweight/obesity, and antihypertensive drugs strategy were correlated with circadian blood pressure profile. Compared with long-acting CCBs, diuretics, ACE inhibitors or ARBs might be helpful in keeping the circadian blood pressure rhythm at normal range.

The Influence of Combined Bisorpolol/hydrochlorothiazide on Morning Blood Pressure Surge in Mild to Moderate Es- sential Hypertension

Effects of combination of bisorpolol and hydrochlorothiazide on circadian blood pressure in the patients with mild to moderate essential hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Reduction of the Morning Blood Pressure Surge Treated with Olmesartan in Chinese Patients with Mild to Moderate Essential Hypertension - A Multicenter, Open-Label, Single Treatment Group Clinical Study

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

[The Clinical Efficiency and Safety of Bisoprolol Hydrochlorothiazide in Patients with Mild to Moderate Essential Hypertension].

Effect of Domestic Produced Bisoprolol Fumarate/Hydrochlorothiazide in Patients with Mild to Moderate Essential Hypertension

Profile on Circadian Blood Pressure and the Influencing Factors in Essential Hypertensive Patients after Treatment

Effects of Compound Hypotensive Tablets Administered at Different Time Points on Pressure Rhythm and 24-Hour Ambulatory Blood Pressure in Patients with Non-dipper Essential Hypertension

The Efficacy of Nebivolol on Patient with Mild or Moderate Mssential Hypertension by Different Smbulatory Blood Pressure Monitoring Methods

PS-C31-2: PRELIMINARY STUDY OF ANTIHYPERTENSIVE TREATMENT EFFECT ON EARLY EVENING ELEVATED BLOOD PRESSURE

Morning Blood Pressure Surge and Blood Pressure Variability in Young and Middle-Aged Essential Hypertensive Patients

The Effects of Olmesartan on Ambulatory Blood Pressures and Blood Pressure Variability in Patients with Mild to Moderate Essential Hypertension

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

Using Different Methods to Evaluate the Efficacy of Olmesartan Medoxomil in Chinese Patients with Mild to Moderate Essential Hypertension According to Ambulatory Blood Pressure Monitoring

Short-term therapeutic effect and safety of combined benazepril and lercanidipine for mild-moderate hypertension

Current Status of Morning Blood Pressure Control and Medication of Hypertensive Patients in Beijing

Preliminary Experiment on the Effect of 18% Substitute Salt on Home Blood Pressure Variability in Hypertensives

Effects of Telmisartan on Mild to Moderate Essential Hypertension Assessed by 48 H Ambulatory Blood Pressure Monitoring

The curative effects and safety of combined therapy of compound reserpine triamterene tablets with other antihypertensives in patients with non dippers type essential hypertension

Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy